(Q36365458)

13 August 2017

1 reference

title

Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease (English)

1 reference

13 August 2017

Marko Lens

1

1 reference

13 August 2017

publication date

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

19

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

9-18

1 reference

Adjuvant therapy in melanoma

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

The biological treatment of renal-cell carcinoma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

European approach to the treatment of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

Interferons: pleiotropic cellular modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

Lessons learned from the Sunbelt Melanoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2005.00051.X

10.1111/J.1529-8019.2005.00051.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference